Amneal Pharmaceuticals, Inc. Stock

Equities

AMRX

US03168L1052

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-05-10 pm EDT 5-day change 1st Jan Change
6.66 USD +2.94% Intraday chart for Amneal Pharmaceuticals, Inc. -1.48% +9.72%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2024 * 2.67B Sales 2025 * 2.79B Capitalization 2.06B
Net income 2024 * -84M Net income 2025 * 23M EV / Sales 2024 * 1.65 x
Net Debt 2024 * 2.35B Net Debt 2025 * 2.12B EV / Sales 2025 * 1.5 x
P/E ratio 2024 *
-24.7 x
P/E ratio 2025 *
95.1 x
Employees 7,850
Yield 2024 *
0.45%
Yield 2025 *
-
Free-Float 26.95%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.94%
1 week-1.48%
Current month+10.08%
1 month+16.84%
3 months+19.57%
6 months+57.82%
Current year+9.72%
More quotes
1 week
6.44
Extreme 6.44
6.84
1 month
5.18
Extreme 5.18
6.90
Current year
5.01
Extreme 5.01
6.90
1 year
1.80
Extreme 1.8
6.90
3 years
1.24
Extreme 1.24
6.90
5 years
1.24
Extreme 1.24
10.04
10 years
1.24
Extreme 1.24
24.48
More quotes
Managers TitleAgeSince
Founder 57 01-12-31
Founder 53 01-12-31
Director of Finance/CFO 57 Nov. 06
Members of the board TitleAgeSince
Director/Board Member 66 Nov. 06
Director/Board Member 69 Nov. 06
Chairman 71 Nov. 06
More insiders
Date Price Change Volume
24-05-10 6.66 +2.94% 1,142,327
24-05-09 6.47 -1.82% 809,186
24-05-08 6.59 +1.23% 904,312
24-05-07 6.51 -2.11% 1,312,618
24-05-06 6.65 -1.63% 1,788,870

Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT

More quotes
Amneal Pharmaceuticals, Inc., is a fully integrated global essential medicine company. The Company is engaged in the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. The Company’s Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermal across a broad range of therapeutic categories. The Company's Specialty segment’s portfolio includes central nervous system disorders (Parkinson’s disease, spasticity, migraine), endocrinology (hypothyroidism), and other therapeutic areas. The Company’s AvKARE segment provides pharmaceuticals, medical and surgical products, and services to government, retail, and institutional markets.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
6.66 USD
Average target price
8.25 USD
Spread / Average Target
+23.87%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW